The purpose of this study is to review the role of dopamine in hypertension and associated conditions. The analysis of literature indicates that present knowledge is mostly based on poor markers and indirect evidence of dopaminergic activity and only few molecular biological data. Alternative markers such as plasma dopamine sulfate emerge as a possible substitute for the low plasma free dopamine detectability, one of the main obstacles in understanding the relationship between circulating dopamine and its receptor actions in hypertension. Essential hypertension represents a heterogeneous entity: based on evidence in borderline and non-modulating hypertension, the tubular dopamine receptor defect may be compensated by increased dopamine synthesis (dopamine ␤-hydroxylase suppression-mediated?) and release; alternatively, compatible with data in stable, salt-sensitive and low renin-
Introduction
It recently became apparent that dopamine (DA) plays a number of important regulatory roles outside the confines of the nervous system, in addition to its well established neurotransmitter function within the brain. Dopamine receptors in cardiovascular tissues, lungs, kidney, gastrointestinal tract and endocrine organs are not yet as clearly delineated as those in the brain. In hypertension, pharmacological actions of drugs acting on some peripheral DA receptors having their genetic make up progressively clarified 1 are becoming of pathogenetic and therapeutic interest.
One of the challenges in defining the role of DA in hypertension (via its physiological vasodilating and natriuretic actions) is to complement indirect evidence using inhibitors of DA synthesis, metabolism and receptors by direct DA measurement. Urinary DA and DA metabolites' excretion are only partly helpful because they depend on many intermediary steps. The measurement of circulating free DA in plasma that would better reflect the peripheral biologically active DA availability at receptor hypertension, the receptor defect may be amplified by a deficient dopamine synthesis, basal and in response to salt and volume expansion. Secondary forms of hypertension (renovascular, renal, polykystic kidneys, mineralocorticoid, pheochromocytoma) associated conditions (renal and heart failure, diabetes, hypovolaemia, mastocytosis) or iatrogenic (cocaine abuse) are mostly reflected by increased dopamine indices, some of them proposed to be counteracting the activation of prohypertensive mechanisms. In conclusion dopamine should thus be monitored in hypertension while respecting several associated conditions affecting peripheral dopaminergic activity. Catecholamine synthesis and metabolism enzymes' and dopamine receptors' targeting are essential for advancing the understanding of dopamine's diagnostic and therapeutic implications.
sites is frequently elusive because free DA concentrations are, unlike free noradrenline (NA) and adrenaline (A), mostly so low that they border the limits of detection. Due to particularities in peripheral DA generation, only a small portion of DA originates in its neuronal spillover while most of DA comes from vastly distributed autocrine-paracrine sources. Many other than neuronal and adrenomedullary tissues (gastrointestinal system, kidney, heart, lung, adrenal cortex, carotid bodies) represent this third catecholamine generating compartment. 2 There is a generous DA synthesis in this compartment due to a wide alimentary and intrinsic availability of the DA precursors tyrosine and dihydroxyphenylalanine (DOPA) and of both tissue enzymes necessary to synthesise DA (tyrosine hydroxylase, aromatic acid decarboxylase). This makes rapid inactivation of considerable homeostatic balance-threatening DA surges (such as following a meal) absolutely essential. Extraneuronal sulfoconjugation of DA evolved as one of the most efficient extraneuronal means to inactivate circulating free DA. 2 Its product DA sulfate may become a complementary or surrogate marker of the overall free DA release 2, 3 provided that a postprandial DA increase is eliminated by several hours of fasting. Sulfoconjugation of DA is also the only reversible metabolic pathway of DA contrasting with its irreversible oxidation and O-methylation. Dopamine sulfate may thus be a temporary storage form of DA overflow but an in vivo free DA gener-ation by DA sulfate deconjugation remains to be proven. Figure 1 summarises multiple determinants of the peripheral biologically active free DA availability at receptor sites exposed to circulation as a balance between DA generation, excretion, metabolism and possibly regeneration. Eventually, the equilibrium between 1-2% of total DA circulating in the free form and 98-99% of total as inactive DA sulfate becomes a determinant of biologically active free DA availability. This review limits its scope to events preceding DA action at receptor site, the latter being covered by a more recent review. 4 Limited knowledge of the DA role in hypertension is partly due to the fact that because of mostly low free DA in plasma only free NA and A are usually determined. DA sulfate measurements as an alternative DA marker become meaningful only when contamination by food or drugs are eliminated. At least 6-8 h fasting 5 and longer elimination of phenols or some enzyme-containing foods (bananas, cereals) or drugs (␣-methyl DOPA, I-DOPA) have to precede DA sulfate determination. The complexity of this system is further amplified by the dependence of multiple enzyme activities on previously summarised genetics, 3 environment and age. 6 The case for monitoring DA in hypertension can be made not only based on the biological action of DA itself but its mutual interactions with NA and A. The antagonistic physiological actions of DA and NA are mostly due to different receptor-mediated vasodilating-vasoconstrictor, natriuretic and antinatriuretic and their mutual release-modulating actions (eg, the presynaptic inhibition of NA release by DA). 7 The DA-NA balance is thus the one to catecholamine limited blood pressure determinants. In this balance, an increased DA release may not be necessarily a primary but a secondary compensatory Figure 1 The peripheral biologically active free DA availability depends on the balance between free DA generation (via DOPA decarboxylation by aromatic acid decarboxylase) on one hand and the DA excretion, metabolism and possibly regeneration on the other. Most of DA originates in its autocrine paracrine synthesis. 2 The peripheral neuronal free DA release (prior to its NA synthesis by dopamine ␤-hydroxylase) and its eventual spillover dependent on the neuronal free DA release-reuptake balance, represents a small contribution to the circulating free DA pool acting at receptor sites. The other side of the balance is dependent on free DA excretion and metabolism which is partly irreversible (Omethylation via catechol-O-methyltransferase COMT and oxidation via mono-amine-O-oxydae MAO) partly reversible (sulfoconjugation via sulfotransferase and deconjugation via sulfatase).
response to increased noradrenergic activity. A possible concomitance between DA and adrenaline (A) responses is recently emerging. Although both DA and A have different biological actions, they have a 'hormonal' character and a higher affinity to sulfoconjugation than NA 3 in common distinct from the predominantly neurotransmitter character of NA. An example of their homeostatic concomitance is the joint DA and A (but not NA) response to protein intake in rats 8 most recently confirmed in man. 9 Catecholamines thus represent an interrelated rather than a sole action on each of the three catecholamine-based regulatory units.
Environmental dopamine responses in relation to hypertension

Dopamine responses to nutritional challenges
The DA responses to environmental changes, their abnormalities in hypertension respectively are highlighted by nutritional challenges ( Table 1 ). The most frequently studied dietary salt loading-induced increased free DA excretion appears to be responsible for natriuresis since DA increase and natriuresis are both prevented by DA synthesis inhibition. 10 The increased urinary free DA following salt loading can be accounted for by increased DOPA spillover into the bloodstream. 11 Renal and extrarenal free DOPA increase appears to be responsible for increased renal excretion of DOPA, DA and sodium in response to salt loading. As demonstrated following salt loading in some brain regions, 12 this increase may relate to a salt-induced enhanced expression of tyrosine hydroxylase (promoting DOPA synthesis) and aromatic acid decarboxylase (promoting DA synthesis) genes' expression. Patients with salt sensitive hypertension were found to have following salt loading an attenuated urinary DA and sodium excretion increase while urinary DOPA excretion increases. 13 This suggests a deficient DA generation from DOPA possibly due to a failure to increase the aromatic acid decarboxylase gene expression by salt. 12 Urinary DA increase does not, however, invariably correlate with sodium excretion following salt loading because of some ethnic DA differences, 14 absence of DA increase in response to a gradually increased oral sodium load 15 and some data indicating that intrarenal DA synthesis has only a minor direct role in the regulation of glomerular filtration and sodium excretion. 16 Despite these controversies DA appears to be under certain conditions one of the mediators of saltinduced natriuresis. The attenuated adaptive DA increase may contribute to salt-sensitive hypertension and to the blunted sodium excretion in normotensive subjects with family histories of hypertension. 17 Protein intake induced-natriuresis was also found to be associated with increased DA excretion attenuated with DA synthesis blockade. 18 The natriuresis-mediated blood pressure decrease by protein intake could explain a wide population-based epidemiological 'INTERSALT' study's observation of inverse relationship between dietary protein and blood pressure. 19 Patients with essential hyperten- sion were found to have a blunted protein intakeinduced urinary DA excretion increase and natriuresis. 20 The blunted urinary DA excretion increase in response to protein could not be most recently confirmed; however, a blunted plasma free DA response was found to be associated with an attenuated natriuresis instead. 9 The plasma free DA response to protein probably escaped attention 18, 20 because the high pressure liquid chromatography (HPLC) techniques used are considerably less sensitive than the radioenzymatic study used in this study. 9 The comparison of salt-and protein-intake-induced DA and natriuresis stimulation suggests that high salt intake results in an increased DOPA-DA portion of the DA synthesis cascade whereas protein intake-induced DA increase originates one step back and may be driven by increased dietary protein originating tyrosine availability as recently observed in protein-fed rats 21 and man. 9 Mammalian DA is an evolutionary salt-expulsory hangover from fish having DA as the main catecholamine adapting them to living in a high salt sea environment. With evolution towards terrestrial life, DA is opposing the catecholamine newcomers, the salt retaining NA and A. 6 In hypertension, the attenuated natriuretic response to both civilization acquisitions, salt and protein, due to NA and A overriding weakening DA responses, pin-points this level of inappropriate adaptation of man to modern lifestyle 22 as a contributor to hypertension.
Dopamine responses to stress
As for other environmental stimuli, it had been known, since the studies of Carlson 23 that the stressinduced plasma free DA increase, parallel to NA and A, may be dramatic and exceeding NA and A two to 10-fold. Because of a short half-life of free DA (2-3 min) which is rapidly conjugated upon release, the magnitude of the DA release is better appreciated by determining, in addition to free DA, also the long half-life (3 h) DA sulfate. 2, 3 As an example of repetitive physical stress, people who regularly exercise have higher DA than untrained sedentary subjects. 24 With plasma DA (and NA) sulfates reflecting the degree of training, 25 acute physical exercise-induced changes in free and sulfated DA (and NA) 24 are compatible with DA release from its sulfate as a possible source of free DA increase additional to the exerciseand training-induced increase in the DA precursor plasma DOPA. 26 Some biological actions of DA, particularly vasodilatation, are probably accountable for certain stressrelated signs such as red hot face, flushing, polyuria and nausea. Plasma DA increases parallel those of NA and A in response to several stimuli in shock, haemorrhage and surgery whereas DA release exceeds that of NA and A in dorsal column (site of DA producing 'small intensively fluorescent cells') stimulation. 27 Selective plasma DA increases were found in post-traumatic stress disorders 28 and hypoxia. 29 The hypoxia-related DA release independent on sympathoadrenomedullary activity may be relevant to a selective DA increase observed in episodically flushing hypertensive patients; 30 in these patients anxiety-associated hyperventilation often accompanies episodic hypertension. 31 Hyperventilation results in respiratory alkalosis-induced decreased oxygen release to tissues which may act as a DA releasing trigger. 29 Detailed mechanisms of free DA increase during stress are not clear. In addition to increased DA synthesis and release, 23 a proposed alternative source of free DA, ie, free DA liberated from DA sulfate by sulfatase-mediated deconjugation 32 remains to be substantiated in vivo. The possibility that DA sulfate represents a reserve pool of free DA released by concomitant glucocorticoid increase-associated stress is supported by the findings that glucocorticoids increase free DA in man. [33] [34] [35] This may be due either to cortisol-induced stimulation of tyrosine hydroxylase 35 the crucial catecholamines synthesising enzyme or of sulfatase activity 36 releasing free DA from DA sulfate, When administering dexamethasone to healthy subjects we have observed 37 a decreased degree of conjugation of DA from 94 ± 2% to 81 ± 6%, P Ͻ 0.05 and NA from 89 ± 2% to 61 ± 9%, P Ͻ 0.01. It is conceivable that an alternative source of free DA would be operative only in the case of considerable cortisol increase-associated stress while moderate homeostatic adjustment to posture and high salt intake 34 could be accommodated by an increased DA synthesis and release. After exhaustive stress magnesium pretreatment shifted the balance from free DA to DA sulfate by a yet unknown mechanism. 38 Variations in response to DA in critical illness were found to be clearly dependent on DA sulfoconjugation.
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Dopamine abnormalities in hypertension
Experimental evidence
Two seminal observations probably account for two basic involvements of DA in blood pressure regulations; the hypotension-inducing dopamine ␤-hydroxylase (D␤H) deficiency resulting in DA excess in humans 40 and, the hypertension-associated defective transduction of the D 1 receptor signal in renal proximal tubules with the mutant mice lacking one or both DA 1A receptor alleles. 41 Dopamine excess is thus promoting hypotension while a defect of its action contributes to hypertension. In the interplay between DA availability and its actions, a DA synthesis defect can be compensated by adaptive upregulation of the DA receptor sites and vice versa a DA receptor defect by an increased DA synthesis and release. An altered hypertensives' responsiveness to environmental stimuli 6 may further modulate this equilibrium; its inadequate balancing has apparent consequences for blood pressure regulation in both directions.
Dopamine ␤-hydroxylase deficiency is a rare disorder in which the major neurotransmitters NA and A are low or absent while DA predominates and becomes the major stress responsive catecholamine. 42 A complete defect results in severe orthostatic hypotension. The inhibition of the rate-limiting tyrosine hydroxylase by metyrosine exerts a hypertensive response 43 confirming that DA excess in the absence of NA was exerting depressor actions.
A probable causal relationship between the DA 1A receptor/signal transduction coupling and hypertension is believed to exist prior to the mice becoming hypertensive; 41 the deletion of receptors from the mice generated by homologous recombination led to hypertension when compared to normal mice. From this point of view, the increased urinary excretion of DA in spontaneously hypertensive rats (SHR) in parallel with the progression of hypertension up to 11 weeks when hypertension is well established. 44 Figure 2 can be viewed as a DA increase compensa- Figure 2 Blood pressure-dependent evolutionary patterns of urinary excretions of free DA and of its neuronal exocytosis-reflecting metabolite 3-methoxytyramine. In the upper part are data in progressively hypertensive SHR 44 compared with Wistar-Kyoto (WKY) rats of the same age remaining normotensive. As hypertension develops, urinary DA excretion increases in SHR but with hypertension fully developed becomes comparable with WKY rats; 3-methoxytyramine excretion increases only in the initial (7 weeks) phase of BP increase but disappears with the progression of hypertension. In the lower panel, left, are data in comparable age control and initial (borderline-) and stable hypertensive subjects. 46 Borderline hypertensive patients have higher urinary free DA excretion than control subjects whereas stable hypertensives have lower free DA excretion. Twenty minutes following 40 mg furosemide i.v. administration, stable hypertensives have less natriuretic and DA excretion response than borderline hypertensives and controls. When comparing age-matched controls, borderline and stable hypertensive patients (lower panel, right) control subjects have an increase in urinary 3-methoxytyramine excretion with age. Considering this age-dependent increase, urinary 3-methoxytyramine excretion was found to be increased only in the younger borderline 47 but not older stable hypertensive patients. 48 tory to the tubular receptor defect. Since the DA metabolite 3-methoxytyramine (3-MT) excretion, best reflecting neuronal DA exocytosis, is also initially increased when hypertension develops, this increase is probably due to an increased neuronal spillover of DA. A similar DA 1 receptor/signal transduction coupling defect was most recently observed in human hypertension. 45 It is therefore of interest to compare these patterns to those observed in human hypertension subdivided into borderline and stable. We see in younger borderline hypertensive patients age-matched increases of urinary free DA 46 and 3-MT excretions 47 followed by normal 3-MT 48 or lower furosemide stimulated urinary DA excretion and natriuresis in older age-matched stable hypertensive patients. 46 Probably compensatory hyperdopaminergic patterns in initial stages of hypertension, subsequently confirmed in SHR 49 and in young borderline hypertensive patients, 50 are associated with a decreased natriuretic response to exogenous DA in SHR. 49 The natriuretic defect contributes to hypertension and volume expansion known to be inducing a D␤H suppression, 51 further perpetuating increased DA syn-thesis. A decreased D␤H activity had indeed been found in specific hypothalamic nuclei 52 and several other tissues of SHR even in prehypertensive stages 53 ( Figure 3) . A human counterpart of these findings may be suppressed serum D␤H responses to stimuli such as posture and furosemide in borderline essential hypertension. 54 The DA abnormality in Dahl salt-sensitive rats is of different nature. Although they also have a defective D 1 -like receptor-mediated cellular signalling mechanism, 55 this defect remained not only uncompensated by increased DA but the DA synthesis appears to be attenuated. This is reflected by decreased kidney DA content in salt-sensitive Dahl rats fed a high salt diet 56 and their deficient increase in urinary DA excretion in response to volume expansion. 57 
Dopamine in essential hypertension
Those experimental data far from being applicable to human hypertension, nevertheless present a background against which human data (Table 1) emerge as two distinct patterns. Borderline hypertensive patients appear to be characterised by an increased Figure 3 Tissue and serum dopamine ␤-hydroxylase (D␤H) activities in hypertension. In the upper part are data in some tissue D␤H activities in prehypertensive (4 weeks old) and hypertensive (12 weeks old) SHR compared to WKY rats. 53 Even in the prehypertensive stage, adrenal D␤H activity is apparently lower in SHR and this becomes evident in the hypertensive stage also in the spleen and heart. In the lower part are human data in hypertension 54 indicating a hyporesponsiveness of serum D␤H to the combined challenge of standing plus furosemide (*P Ͻ 0.05).
basal exocytotic DA release probably preceded by accelerated DA generation from DOPA, 47 accentuated by D␤H suppression 54 and reflected by increased urinary DA excretion. 46, 50 Non-modulating hypertensives who are mostly borderline were found to have increased plasma free DA. 58 The source of this hyperdopaminergic condition remains unexplained. Hypothetically, it could represent a compensatory response to a DA 1 receptor defect recently claimed to exist in man. 45 An alternative view of borderline (labile or episodic) hypertension and their increased dopamine became apparent when also DA sulfate concomitantly with free DA, NA and A, their sulfates respectively, were determined in an unselected cohort of essential hypertensive patients. Their mean plasma DA sulfate concentrations are higher than in control subjects, 59 as recently confirmed. 60 A closer analysis has shown that the mean DA sulfate increase is due to a subgroup of borderline hypertensive patients, particularly those with anxiety-related episodic hypertension. 30, 35 In addition, most of the patients with high DA sulfate had a decreased NA and A sulfoconjugation. 61 Since phenolsulfotransferase activity and sulfate availability are limit-ing factors in sulfoconjugation, it is conceivable that the high affinity DA sulfoconjugation occurs at the expense of the lower affinity NA and A conjugation and affect the biological impact of both antagonistic systems; low sulfoconjugation may increase the availability of free NA and A and their prohypertensive action whereas high sulfoconjugation decreases the free DA availability and its antihypertensive action. 62 An alternative explanation of an altered dopamine NA relationship in hypertensives is that a defective dopaminergic control in the central nervous system 63 yields excessive central and peripheral noradrenergic discharge.
Stable, salt-sensitive and low renin hypertension probably identifies hypertensives with a DA synthesis defect. Urinary free DA responses to salt loading were found to be defective in salt-sensitive 64 and low renin 65 hypertension. Concomitant measurements of DOPA and DA in urine have suggested a decreased DOPA decarboxylation or defective tubular DOPA uptake in salt-sensitive hypertension. 13 Following oral DOPA administration, stable 48 and low renin hypertensive patients 65 were found to have a lower degree of DOPA decarboxylation to free DA than control subjects. Those hypertensive subgroups apparently have a defect of DA generation from DOPA which may result in adaptive even if relative DA 1 receptor changes; DA receptor upregulation from initially decreased responsiveness or its decreased occupancy is suggested by an exaggerated natriuretic response to exogenous DA in low renin hypertension. 66 Furthermore, a hypernatriuresis and excessive blood pressure decline in response to DOPA was observed in stable hypertensive patients despite their lower DA generation from DOPA. 48 The urinary cyclic AMP hyperresponsiveness to DA infusion in these patients 67 is also compatible with an upregulation of the adenyl-cyclase component of the DA 1 -like receptor. Since salt sensitivity exists in normotensive subjects and may be heritable, it is conceivable that it can precede the appearance of hypertension. Its possible relationship to a suppressed dopaminergic activity in young normotensive subjects with apparent family history of hypertension who had a blunted sodium excretion before any evidence of hypertension emerged, 17 will merit further investigation.
Patients with essential hypertension represent thus at least two distinct dopaminergic abnormalities dependent on what form or stage of hypertension is studied. The hyperdopaminergic features of borderline hypertension 46, 47, 50 remain unexplained. With hypertension progressing into the stable form, the dopaminergic activity is weakening. 46, 48 Stable, salt-sensitive and low renin hypertension apparently share a defect in DA synthesis. Further multicentre studies using comparable DA indices and criteria for sub-categories of hypertension will be needed to substantiate the essential hypertension division into two unrelated or evolutionary stages 46 of DA abnormalities and their therapeutic implications.
Dopamine in secondary hypertension and associated conditions
Secondary forms of hypertension are known to be associated with increased plasma DA as observed for DA sulfate in renal 35 and renovascular 60 hypertension. In primary aldosteronism the initial DA sulfate increase was reversible following the adrenal tumor excision 68 suggesting its secondary character. Patients with primary aldosteronism were also found to have an increased renal DA generation from DOPA. 69 Increased plasma free and conjugated DA was observed in diabetics 70 in whom DA increase may be compensating their disturbed renal dopaminergic system. The existence of such a defect and its inherited linkage to hypertension is suggested by the finding that even normotensive patients with insulin-dependent diabetes, but family history of hypertension, have a defective renal DA and natriuretic response unlike those with negative family history of hypertension. 71 In diabetics the absence of nephrogenic cyclic cAMP formation (a marker of the proximal tubular brush border membrane-mediated nephrogenous cyclic AMP-linked DA 1 receptor 4 in response to DA, 72 is compatible with a DA 1 -like receptor defect.
Patients with autosomal polycystic kidney disease and borderline hypertension were found to have increased urinary DA excretion at all levels of sodium intake. 73 A compensatory DA increase may probably be needed to maintain sodium excretion in the presence of a decreased renal tubular mass, the main target of DA's natriuretic action.
Normo-or hypertensive renal insufficiency patients have increased plasma DA sulfate, reversible by haemodialysis 74 due to the decreased renal clearance of DA sulfate 75 affecting also exogenous DA clearance in critical illness. 39 Although chronic renal failure is associated with increased plasma DOPA and DA sulfates 76 their real impact may be opposite. DA sulfate appears to be an endogenous inhibitor of several proper biological free DA action. 77 Consequently, a predominantly efferent glomerular vasodilation, one of the renal DA actions may be attenuated, contributing so to intraglomerular hypertension, a hallmark of renal damage due to hypertension. 78 It is conceivable that the decreased renal clearance of DA sulfates observed in hypertensive patients without renal failure 79 represents a potential precursor of the steeply decreased renal clearance of DA sulfate in chronic renal failure 74 temporarily reversible by haemodialysis. 75 Dopamine excess originating in neoplastic tissues includes dopamine-producing pheochromocytoma which carries less than previously suspected the connotation of malignity. 80 Hypersecretion of DA can usually be detected by elevated plasma free DA 34 and DA sulfate. 34, 68 The hyperdopaminergic condition, in which outpouring of DA from the tumor overwhelms the patient's ability to conjugate, 81 is usually reflected by normo-or hypotension. It rarely results in an increased outlet resistance of the prostatic urethra reversible after partial excision of the tumor and decreased DA concentration. 82 A very particular newly recognised form of DA discharge from autonomously secreting cells are DA surges in mastocytosis occasionally suspected of pheochromocytoma because of blood pressure instability. Mastocytes are known to contain DA 83 and mastocyte-like pulmonary cells were found to contain mRNA for tyrosine hydroxylase 2 the crucial enzyme in autocrine-paracrine DA synthesis. When comparing baseline and blood pressure swings-associated episodic concentrations of catecholamines and DA sulfate, several-fold DA sulfate (unlike free DA) increases were observed during these episodes. 84 This increase probably reflects free DA release which may, prior to rapid sulfoconjugation, contribute to flushing during these episodes and the rarely also observed polyuria and nausea.
Dopamine increase reflecting sympathetic discharge compensatory to decreased cardiopulmonary volume is most evident in heart failure and reflected by increased DA sulfate. 85 In patients with idiopathic dilated cardiomyopathy exposed to exercise, plasma DA sulfate proved to be an even better marker of sympathetic discharge than free NA. 86 DA receptors were found not only in the kidney but also in the heart 87 and to be involved in heart failure. Increased DA is probably balanced by DA receptor downregulation in the failing heart protecting it against further DA stimulation. This may explain why a treatment trial by a DA 1 and DA 2 receptor agonist ibopamine in severe heart failure had to be interrupted because of an excess of deaths in the ibopamine group. 88 A particular condition in which DA release compensatory to decreased cardiopulmonary volume may be operative is idiopathic hypovolemia. This syndrome is associated with pheochromocytomaimitating 84 episodes of hyper-or hypotension associated with flushing and palpitations. Its association with DA sulfate surges, while the NA reflected sympatheric arousal is inappropriately low to the degree of hypovolaemia, suggests that the DA discharge may compensate for this defect; DA stimulated by hypovolaemia may cause a self-perpetuating vicious circle by further promoting hypovolaemia by its natriuretic action. 89 Other identifiable abnormalities affecting free catecholamines availability, potentially affecting blood pressure are defects in DA and NA conjugation and their disposal via sulfoconjugation are in patients with migraine who were found to have the activity of the M form of phenolsulfotransferase responsible for DA and NA sulfation reduced 90 and further inhibited by red wine. 91 Consequently, DA and NA may be insufficiently sulfoconjugated and by their higher biological activity free DA may contribute to vasodilation (characterising migraine) and free NA to hypertension. Blood pressure regulation-related may also be the alcohol-induced DA sulfate increase in non-alcoholics whereas alcoholics had less response to alcohol. 92 This alcoholic's failure may contribute to hypertension by less DA generation resulting from their altered DA derivative salsolinol formation in response to alcohol. Increased DA sulfate in plasma was recently observed in cocaine addicts. 93 It apparently reflects the DA re-uptake inhibition by cocaine ('the pleasure pathway') with DA overflow undergoing rapid sulfoconjugation. A parallel cocaine action on NA reuptake is occasionally associated with pheochromocytoma-imitating hypertensive episodes. 84 Amphetamine administration is also associated with extracellular DA 94 and parallel NA increases; while DA is related to psychostimulation, NA to episodic hypertension by ␣ 1 , receptor stimulation.
Diagnostic and therapeutic implications
These DA abnormalities in several hypertensive and related conditions suggest that the main reason of inconsistencies and lack of knowledge in this field is a dearth of good markers of peripheral DA activity. At the present knowledge, essential hypertension is associated with two distinct DA paradigms: an increased DA synthesis and release in borderline or non-modulating hypertension or decreased DA synthesis in salt-sensitive, low renin and stable hypertension. In some secondary forms of hypertension increased DA may be compensatory to the sodium retaining actions of 1 o and II o hyperaldosteronism, to a decreased renal tubular mass (polykystic kidney) or be of autonomous neoplastic origin.
Plasma DA measurements complementing those of NA and A may thus be helpful in hypertension. Radioenzymatic determination 9, 34 is preferable to the less sensitive HPLC techniques. Plasma DA sulfate under controlled conditions is at present a surrogate even if imperfect DA marker substituting for low plasma free DA detectability. More suitable peripheral dopaminergic indices have to be explored. Sympathoneuronal imaging by 6-(18F) fluorodopamine, confirming extraneuronal sulfoconjugation of DA 95 is a promising approach in the brain but not yet tested in the periphery. Several enzymes involved in DA synthesis metabolism and action and their recognised abnormalities 62 make DA synthesis, metabolism and action candidates for enzyme targeting. 96 Increased density of peripheral mononuclear cell D3 receptor progressing with human diastolic hypertension 97 may represent an upregulation mechanism consequent to the progressively decreasing dopaminergic function with evolution of hypertension. 46 Therapeutic interventions such as dopaminomimetic drugs 98 or prodrugs, 88 an augmentation of the renal tubular DA activity by oral calcium supplementation, 99 competitive inhibition of catecholamine sulfoconjugation by oral ascorbic acid administration making more free DA available 100 or D␤H inhibition 101 are potential strategies in modulating the free DA availability or promoting its action in hypodopaminergic hypertension. The DA 1 receptor agonist, Fenoldopam, appears to be a promising drug used i.v. as an alternative to nitroprusside in hypertensive crises. 102 However, the use of dopaminomimetic drugs in hypertension must also consider other associated conditions. The potential danger of a uniform dopaminomimetic approach is demon-strated by excess mortality in the treated group in the randomised ibopamine heart failure study. 88 
